Christopher O’Donnell

Christopher O’Donnell

Company: Novartis Institutes of Biomedical Research

Job title: Global Head, Cardiovascular & Metabolism Translational Medicine

Seminars:

Translating Biomarker & Quality of Life Evaluation into Precision Medicine Approaches in HFpEF 1:45 pm

Describe risk factors and disease endotypes in evaluation for HFpEF clinical trials Define the state of proteomic/genomic, digital and cardiac imaging in precision medicine evaluation of HFpEF symptoms and disease progression Discuss the evolving landscape of HFpEF clinical trials and opportunities for precision medicineRead more

day: Day Two

Moderated Discussion – Outlining Methods to Improve the Quality of Life for HFpEF Patients 2:15 pm

What has been observed in previous trials with respect to mortality rates and what have interim analyses shown? What steps have been taken to improve this definition for HFpEF patient? How does changing the definition for quality of life subsequently alter the drug development industry?Read more

day: Day Two

Moderated Discussion – Consideration of Gene Therapy Effectiveness Resulting from Insights into Genetic Predisposition 5:45 pm

Read more

day: Day One

Panel Discussion – Could Imaging be Taken Further? Thinking Unconventionally About Diagnosis 3:30 pm

Read more

day: Day One

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.